Ona Therapeutics, a biopharmaceutical firm specializing in treatment-resistant cancers, has successfully closed an oversubscribed Series B financing round, securing $86.6 million. The funding was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with strong participation from existing backers. This capital injection is set to propel the company's innovative antibody-drug conjugate (ADC) programs into crucial clinical development stages.
Strategic Allocation of Capital
The proceeds will primarily support the clinical advancement of Ona's lead program, ONA-255, a first-in-class ADC for breast cancer. This funding is crucial for moving the candidate toward achieving clinical proof of concept. ONA-255 is engineered with a differentiated mechanism to improve the therapeutic index and address the complex biology of treatment-resistant tumors.
In addition to its lead candidate, the company will progress its second program, ONA-389, which targets colorectal cancer. The financing will enable ONA-389 to advance toward first-in-human clinical trials, broadening the company's impact on diseases with high unmet needs. Ona Therapeutics currently maintains full worldwide commercial rights for all assets within its pipeline, ensuring strategic control over its innovations.
Investor Confidence and Vision
The oversubscribed nature of the round highlights strong investor confidence in Ona's mission and scientific platform. The syndicate includes new co-leads Columbus Venture Partners and Mérieux Equity Partners, alongside COFIDES and Korys. All existing investors, including Alta Life Sciences and Ysios Capital, also participated, demonstrating unified support for the company's next growth phase.
Investor representatives expressed optimism about the company's future, citing its world-class science and clear path to clinical impact. Jose Mesa of Columbus Venture Partners praised Ona's focus on cancer resistance, a significant challenge in oncology. Valérie Calenda of Mérieux Equity Partners highlighted the team's deep biological insight and the compelling preclinical data for ONA-255.
Innovative Approach to Oncology
Ona Therapeutics is pioneering a differentiated pipeline of ADCs focused on cancers with limited treatment options. The company utilizes a proprietary, patient-driven target discovery platform to identify novel tumor-specific antigens. This enables highly efficient internalization of the ADC and targeted delivery of its therapeutic payload directly to cancer cells.
This sophisticated approach is designed to maximize therapeutic efficacy while simultaneously minimizing on-target toxicities in healthy tissues. By focusing on unique biological mechanisms, Ona aims to overcome the key drivers of drug resistance in advanced tumors. This strategy provides a compelling opportunity to build a differentiated platform that can address significant unmet medical needs for patients.
Leadership and Corporate Growth
This financing marks a pivotal inflection point for Ona, supporting its transition from a preclinical to a clinical-stage company. The immediate focus will be on generating initial human safety and efficacy data for ONA-255. This step is critical for validating the company's platform and advancing its lead asset toward regulatory milestones and potential market entry.
The company's growth is guided by a highly experienced leadership team, including Board Chair Antoine Yver and Chief Medical Officer Jutta Amersdorffer. In connection with the financing, the Board of Directors will be strengthened by the addition of Jose Mesa, Valérie Calenda, and Eva Van Overmeire. Their collective expertise will be instrumental in navigating the next phase of clinical development and corporate expansion.
With $86.6 million in new funding, Ona Therapeutics is well-positioned to advance its pioneering work in oncology. The capital will accelerate the clinical development of its lead ADC programs for breast and colorectal cancer, backed by a syndicate of high-quality investors. This strategic financing empowers the company to pursue its mission of developing meaningful therapies for patients with treatment-resistant cancers.